The Biostatistics, Bioinformatics and Epidemiology Program (BBE) supplies the statistical and mathematical modeling expertise needed within Fred Hutch’s Vaccine and Infectious Disease Division to accomplish our ambitious objective of eliminating disease and death attributable to infection. We are also accelerating research to confront the growing burden of COVID-19, HIV and cancer-related infectious diseases worldwide.
BBE's nearly 34 faculty members model epidemics, research statistical methods to design complex global clinical trials, and analyze biological assays to better understand infectious disease processes and immune responses.
A hallmark of BBE is the simultaneous pursuit of excellence in both methodological and applied science. Researchers frequently develop novel mathematical approaches to better answer scientific questions that continually emerge from ongoing studies within the division.
Fred Hutch directs major worldwide, multicenter studies to model the spread of infectious diseases and to combat the global HIV/AIDS epidemic. Our biostatisticians play leadership roles in these initiatives.
Dr. Elizabeth “Betz” Halloran is a world leader in using mathematical and statistical methods to study infectious disease. She is a pioneer in the field of designing and analyzing vaccine studies, including studies of HIV vaccines. In addition to being Program Head of VIDD’s Biostatistics, Bioinformatics & Epidemiology Program, she is the director of the Center for Inference and Dynamics of Infectious Diseases. Headquartered at Fred Hutch, this center helps the federal government understand and prepare for infectious-disease outbreaks. She is also the founder and Director of the Summer Institute in Statistics and Modeling in Infectious Diseases at the University of Washington’s School of Public Health. Her work is used to develop strategies to stop outbreaks of serious global threats such as Zika, Ebola and SARS-CoV-2 virus diseases, influenza, cholera and dengue fever.
In recent months Betz has taken a leading role in advising local, regional and global governments on matters relating to the SARS-CoV-2 pandemic, notably as a participating member of the World Health Organization’s Blueprint for Research & Development Working Group on Trial Design for Emerging Infectious Diseases, as well as its Scientific Advisory Group.